IGM Biosciences, Inc. (IGMS)
| Market Cap | 1.91B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -81.36M |
| Shares Out | 30.75M |
| EPS (ttm) | -26.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $59.45 |
| Previous Close | $59.69 |
| Change ($) | -0.25 |
| Change (%) | -0.41% |
| Day's Open | 58.65 |
| Day's Range | 58.00 - 60.71 |
| Day's Volume | 80,034 |
| 52-Week Range | 41.41 - 133.00 |
STOCKHOLM, April 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its Board of Directors appoints Magnus Christensen, the company's CFO, as interim CEO of Medivir. Magnu...
STOCKHOLM, April 6, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2020 now is available at the company's website: www.medivir.com. In the spring of ...
STOCKHOLM, March 31, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during March 2021 as a result of the previously a...
– Recommended Phase 2 Dose for IGM-2323 Expected in 2021 –
STOCKHOLM, March 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the last patient with advanced liver cancer has been included in the first part of the phase Ib study w...
MOUNTAIN VIEW, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...
STOCKHOLM, March 22, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that Yilmaz Mahshid leaves the position as CEO of Medivir. The nomination committee proposes that he is elec...
HUDDINGE, Sweden, March 11, 2021 /PRNewswire/ -- Resolution on a directed issue of shares The extraordinary general meeting in Medivir Aktiebolag (publ) on 11 March 2021 resolved, in accordance with the...
STOCKHOLM, March 8, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright Global Life Sciences Conference, March 9...
STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during February 2021 as a result of the previously...
MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...
STOCKHOLM, Jan. 12, 2021 /PRNewswire/ -- Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences, Inc. (Nasdaq...
- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors - - IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors -
MOUNTAIN VIEW, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...
Short squeezes don't typically live up to their expectations.
MOUNTAIN VIEW, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the closing of its upsized underwritten public offering of 1,221,224 shares of its com...
MOUNTAIN VIEW, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the pricing of its upsized underwritten public offering of shares of its common stock ...
MOUNTAIN VIEW, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $150 million of shares of its common stock and, in lieu of...
- 9 of 14 P atients S howed R eduction in T umor S ize, I ncluding T wo R ecently R eported C omplete R esponses -
MOUNTAIN VIEW, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...
MOUNTAIN VIEW, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...
MOUNTAIN VIEW, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...
MOUNTAIN VIEW, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- - Initial D ata from Phase 1 T rial of IGM-2323 in R elapsed/ r efractory N on-Hodgkin's L ymphoma to be Presented at the 62nd American Society o...
- Abstract Shows Encouraging Safety and Cytokine Release Data, Preservation of T cell Function and Repeatable T cell Activation - - Abstract Shows Encouraging Safety and Cytokine Release Data, Preservat...
MOUNTAIN VIEW, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...
- Multi-year, Multi-target Agreement Intended to Expedite Discovery of Novel IgM Antibodies - - Multi-year, Multi-target Agreement Intended to Expedite Discovery of Novel IgM Antibodies -
Analysts also positive on Charles River, Gilead and Horizon Therapeutics
IGM Biosciences (IGMS) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
The firms that we cover on Wall Street increasingly are starting to agree that the volatility the stock market is encountering now, and the beating the economy has taken this year, should continue to fa...
MOUNTAIN VIEW, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, tod...
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the second quarter e...
MOUNTAIN VIEW, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, toda...
- Companies to utilize proprietary platforms to discover, develop, and manufacture potential therapeutic antibodies to combat ongoing COVID-19 pandemic -
Clinical trial successes could send shares of these drugmakers screaming higher.
IGM Biosciences, Inc. (IGMS) CEO Fred Schwarzer on Q4 2019 Results - Earnings Call Transcript
After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfo...
IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis
- Expert in the research and development of apoptotic pathways and antibody drug conjugates - - Expert in the research and development of apoptotic pathways and antibody drug conjugates -
Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for investors who ...
About IGMS
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L... [Read more...]
| Industry Biotechnology | IPO Date Sep 18, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol IGMS |
Analyst Forecasts
According to 8 analysts, the average rating for IGMS stock is "Buy." The 12-month stock price forecast is 101.63, which is an increase of 70.96% from the latest price.